Helius Medical Announces Results from a Case Series of Subjects with Advanced MS

NEWTOWN, Pa.–(BUSINESS WIRE)–Helius Medical Technologies, Inc. (TSX: HSM, HSM.S, OTCQB: HSDT)
(“Helius” or the “Company”) is pleased to announce the results of a case
series of individuals with advanced symptoms of Multiple Sclerosis (MS)
treated with PoNS™ Therapy.
This study was performed at TCNL¹, University of Wisconsin,
Madison and the data was presented at the 2016, Annual Meeting of the
Consortium of Multiple Sclerosis Centers (CMSC).
Six subjects with advanced MS (Expanded Disability Status Scale (EDSS)²
scores ranging from 6.5 to 7.5) were enrolled in a six-month pilot
study. Subjects were trained in PoNS™ Therapy which combines use of the
prototype PoNS™ device with physical training in balance, gait, movement
and postural stability. Results demonstrated improvements in physical,
cognitive and quality of life parameters. The demanding training regimen
also resulted in significant real life improvements such as re-adopting
a walker for community mobility, decreased fatigue, increased
independence with daily activities, overcoming physical obstacles at
home and increased community access.
“Those with greater functional ability at the beginning of the study
(EDSS 6.5-7.0) made the most significant gains but all subjects could be
qualified as improved. The intervention shows promise to prolong
functional ambulation and independence with daily activity,” said
Principal Investigator Mitch Tyler.
In a separate MS Pilot study, sponsored by Helius (see press release
November 2, 2015), the average EDSS score of the subjects was 4.5, while
the average in this subject pool was 7.0. In applauding the efforts of
the TCNL investigators, Helius CEO Phillippe Deschamps noted, “The
patients in this study represent a much more challenging cohort and
received PoNS^TM Therapy for a longer period (6-months vs.
14-weeks), yet compliance remained high. The outcome is very
encouraging.”

About PoNS™ Therapy
The Portable Neuromodulation Stimulator (PoNS™) is an investigational
non-invasive device designed to deliver neurostimulation through the
tongue. PoNS™ Therapy combines the use of the device with physical
therapy and is currently being evaluated in a multicenter clinical trial
for the treatment of balance disorder for subjects with mild to moderate
Traumatic Brain Injury.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a medical technology company focused on
neurological wellness. Helius seeks to develop, license and acquire
unique and non-invasive platform technologies that amplify the brain’s
ability to heal itself. Helius intends to file for FDA clearance for the
PoNS™ device. For more information, please visit www.heliusmedical.com.
The Toronto Securities Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the content of this news
release.
Cautionary Disclaimer Statement:
Certain statements in this news release are not based on historical
facts and constitute forward-looking statements or forward-looking
information within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and Canadian securities laws (“forward-looking
statements”).
All statements other than statements of historical fact included in this
news release are forward-looking statements that involve risks and
uncertainties. Such forward-looking statements include, among others,
statements regarding ongoing or planned clinical research, expected
future development timelines, regulatory approvals, business initiatives
and objectives and use of proceeds from financings or other business
initiatives.
Forward-looking statements are often identified by terms such as “will”,
“may”, “should”, “anticipate”, “expects” and similar expressions.
There can be no assurance that such statements will prove to be accurate
and actual results and future events could differ materially from those
anticipated in such statements. Important factors that could cause
actual results to differ materially from the Company’s expectations
include the failure of the Company to achieve its business objectives
and other risks detailed from time to time in the filings made by the
Company with securities regulators.
The reader is cautioned that assumptions used in the preparation of any
forward-looking statements may prove to be incorrect. Events or
circumstances may cause actual results to differ materially from those
predicted, as a result of numerous known and unknown risks,
uncertainties, and other factors, many of which are beyond the control
of the Company. The reader is cautioned not to place undue reliance on
any forward-looking statement. Such information, although considered
reasonable by management at the time of preparation, may prove to be
incorrect and actual results may differ materially from those
anticipated. Forward-looking statements contained in this news release
are expressly qualified by this cautionary statement. Risks and
uncertainties about the Company’s business are more fully discussed in
the Company’s disclosure materials, including the short form prospectus
filed in connection with the Offering, its Annual Report on Form 10-K
filed with the United States Securities and Exchange Commission and the
Canadian securities regulators and which can be obtained from either at www.sec.gov
or www.sedar.com.
The forward-looking statements contained in this news release are made
as of the date of this news release and the Company assumes no
obligation to update any forward-looking statement or to update the
reasons why actual results could differ from such statements except to
the extent required by law.